PCA
VRTX icon

Providence Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Providence Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18
Closed -$3K – 290
2019
Q1 		$3K Buy
+18
New +$3.33K ﹤0.01% 247

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Providence Capital Advisors's VRTX Position: Q2 2019 in Review

Providence Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 18 shares — an estimated $3K sold.

Providence Capital Advisors first reported a position in VRTX in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

  • Providence Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Providence Capital Advisors sold 18 Vertex Pharmaceuticals shares in Q2 2019, an estimated $3K.
  • Providence Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Providence Capital Advisors's Vertex Pharmaceuticals position peaked at $3K in Q1 2019.
  • 716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Providence Capital Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.